DLBS1033 for the Treatment of Acute Ischemic Stroke

Acute Ischemic Stroke Clinical Trial

Official title:

The Role of DLBS1033 in the Management of Acute Ischemic Stroke Patients: A Randomized Controlled Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02362984
• Other study ID #: DLBS1033-0614
• Status: Terminated
• Phase: Phase 3
• First received: February 3, 2015
• Last updated: May 2, 2017
• Start date: October 2014
• Est. completion date: April 2017

Study information

• Verified date: May 2017
• Source: Dexa Medica Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, randomized, double-blind, and controlled clinical study to investigate the effects of DLBS1033 in conjunction with standard therapy compared to standard therapy alone in acute ischemic stroke patients.

Description:

Patients included into the study will be randomized into two groups and receive either standard therapy alone (as control group) or standard therapy plus DLBS1033 at a dose of 490 mg three times daily (as DLBS1033 group). Standard therapy used in the study will consist of: aspirin 80 mg, simvastatin 20 mg, vitamin B complex, and citicholine 250 mg/2 mL twice daily.

After hospital admission and diagnosis, patient will be handled according to the standard management for acute ischemic stroke applicable in the hospital. Right after the patient is confirmed eligible to the study, the treatment(s) will be switched immediately into the study's regimens. Clinical and laboratory examinations to evaluate the investigational drug's efficacy will be performed at baseline, day 4, and day 8 of treatment (end of study); while safety examinations will be performed at baseline and end of study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: April 2017
• Est. primary completion date: February 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male or female subjects with age of 18-75 years .

• Has been diagnosed with acute ischemic stroke clinically confirmed by CT scan.

• Modified National Institutes of Health Stroke Scale (mNIHSS) score >= 5.

• Patients present at hospital and receiving first dose of study medication within 72 hours after the onset of the stroke symptoms.

• Able to take oral medication.

Exclusion Criteria:

• For females of childbearing potential: pregnancy and lactation period.

• History of or current hemorrhagic stroke (within the last 3 months).

• Transient ischemic stroke (TIA).

• Patients with seizure at the onset of stroke.

• History of serious head injury within the last 3 months.

• History of major surgery within the last 3 months.

• Serious cardiovascular conditions, such as myocardial infarction, CHF grade III and IV (NYHA classification), aorta dissection, and atrial fibrillation within the last 6 months.

• Presence of severe renal or hepatic dysfunction

• Presence of acute or chronic infections.

• Thrombocytopenia (thrombocytes level < 150.000/ul).

• Patients with higher risks of bleeding.

• Uncontrolled hypertension (systolic blood pressure > 185 mmHg or diastolic blood pressure > 110 mmHg).

• Random plasma glucose >= 200 mg/dL.

• Current or regular use of oral anticoagulants, antiplatelets other than study medication, and herbal medicines.

• Hypersensitive to the investigational product(s).

Related Conditions & MeSH terms

• Acute Ischemic Stroke
• Cerebral Infarction
• Ischemia
• Stroke

Intervention

Drug:
• Placebo
Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
• DLBS1033
DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily

Locations

Country	Name	City	State
Indonesia	RSUD R. Syamsudin, SH	Sukabumi	West Java

Sponsors (1)

Lead Sponsor	Collaborator
Dexa Medica Group

Country where clinical trial is conducted

Indonesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement in mNIHSS score	Change in functional outcomes as measured by The Modified National Institute of Health Stroke Scale (mNIHSS) from its baseline value	7 days after treatment initiation
Secondary	Improvement in MRS	Change in functional outcomes as measured by Modified Rankin Scale (MRS) from its baseline value	7 days after treatment initiation
Secondary	Improvement in fibrinogen level	Change in haemostatic parameter as measured by fibrinogen level from its baseline value	7 days after treatment initiation
Secondary	Improvement in d-dimer level	Change in haemostatic parameter as measured by d-dimer level from its baseline value	7 days after treatment initiation
Secondary	Liver function	Liver function measured will be: serum AST, ALT, G-GT, total bilirubin	7 days after treatment initiation
Secondary	Renal function	Renal function measured will be serum creatinine	7 days after treatment initiation
Secondary	Routine hematology	Routine hematology measured will be: hemoglobin, hematocrit, RBC, WBC, differentiation of WBC, and platelet count	7 days after treatment initiation
Secondary	Hemostasis parameters	Hemostasis parameters measured will be: PT and aPTT	7 days after treatment initiation
Secondary	Adverse events	Adverse events, including bleeding events, will be observed and carefully evaluated during the expected average of 7 days of study treatment.	7 days after treatment initiation